Rhythm Pharmaceuticals (RYTM) Other Accumulated Expenses (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has reported Other Accumulated Expenses for 10 consecutive years, with $3.4 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Other Accumulated Expenses fell 90.73% year-over-year to $3.4 million; the TTM figure through Sep 2025 stood at $3.4 million (down 90.73% YoY), while the FY2024 annual figure was $37.7 million, up 596.93% from the prior year.
• Other Accumulated Expenses fell to $3.4 million in Q3 2025 per RYTM's latest filing, from $4.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $37.7 million in Q4 2024 and bottomed at $229000.0 in Q1 2021.
• Historically, Other Accumulated Expenses has averaged $6.8 million across 5 years, with a median of $3.4 million in 2025.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses jumped 876.15% — and 2025, when it plunged 90.73%.
• Rhythm Pharmaceuticals' Other Accumulated Expenses stood at $800000.0 in 2021, then surged by 202.38% to $2.4 million in 2022, then surged by 123.65% to $5.4 million in 2023, then soared by 596.93% to $37.7 million in 2024, then plunged by 90.99% to $3.4 million in 2025.
• Business Quant data shows RYTM's Other Accumulated Expenses at $3.4 million in Q3 2025, $4.4 million in Q2 2025, and $5.8 million in Q1 2025.